
About Maitri Enterprises
Maitri Enterprises is a publicly listed company based in Ahmedabad (India) founded in 1991. Pharmaceutical products and medical devices are distributed in India. Its Indian entity Maitri Enterprises Limited reported revenue of βΉ33.72 Cr. Maitri Enterprises offers products and services including Corporate Services. Its focus areas include Medical Device Distributors, Pharmaceutical Distributors and Diversified. Similar companies include Entero Healthcare, Keimed and Sandor Medicaids; 3 of its 3 listed similar companies have raised funding.
Company details
Maitri Enterprises was established in 1991 and is headquartered in Ahmedabad, India. Operations focus on the distribution of pharmaceutical products and medical devices within the healthcare sector. The company is managed by Jaikishan R Ambwani as Managing Director. Activities encompass supply chain logistics and product sourcing for regional markets, supporting medical and pharmaceutical needs across the country.
- Headquarters Ahmedabad, India
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website maitrienterprises.com
- Legal Name Maitri Enterprises Ltd.
- Market Cap₹14.34 Cr
MAITRI · BSE
- Share Price₹32.59
0.00% today
- Revenue₹33.30 Cr
FY 2025-26 · +16.0% YoY
- EBITDA₹1.29 Cr
Margin 3.9%
- Net Profit₹0.60 Cr
FY 2025-26 · -37.5% YoY
- P/E (TTM)18.0x
P/B 2.9x
Associated legal entities of Maitri Enterprises
Maitri Enterprises is associated with 2 registered companies on The Company Check; the primary company is Maitri Enterprises Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Maitri Enterprises Limited Listed CIN L45208GJ1991PLC016853 | Active | 30 Dec 1991 | Ahmedabad, Gujarat | ₹33.7 Cr | 7 | View details | |
| Dr Zag Ambwani (India) Llp CIN AAR-9790 | Active | 19 Feb 2020 | Ahmedabad, Gujarat | 4 | View details |
Products & Services of Maitri Enterprises
Maitri Enterprises offers a comprehensive portfolio of products and services, including Corporate Services.
Manages company governance and compliance information
Board of directors of Maitri Enterprises Limited (Maitri Enterprises)
Maitri Enterprises Limited is the primary company behind Maitri Enterprises. The boards of the 2 registered companies of Maitri Enterprises currently have 8 directors; the longest-serving is Rameshlal Ambwani Bullchand, appointed in 2011. 20 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rameshlal Ambwani Bullchand DIN 02427779 | Director | 14 Jul 2011 | 15 yrs 3 mo | Maitri Enterprises Limited |
| Nilesh Carpenter DIN 08704659 | Designated Partner | 19 Feb 2020 | 6 yrs 8 mo | Dr Zag Ambwani (India) Llp |
| Sarla Jaikishan Ambwani DIN 06712878 | Designated Partner | 19 Feb 2020 | 6 yrs 8 mo | Dr Zag Ambwani (India) Llp, Maitri Enterprises Limited |
| Chanderlal Ambwani Bulchand DIN 01390563 | Designated Partner | 19 Feb 2020 | 6 yrs 8 mo | Dr Zag Ambwani (India) Llp |
| Jaikishan Rameshlal Ambwani DIN 03592680 | Designated Partner | 25 Jun 2020 | 6 yrs 4 mo | Dr Zag Ambwani (India) Llp, Maitri Enterprises Limited |
| Deepak Ambwani DIN 03054773 | Director | 10 Nov 2020 | 5 yrs 11 mo | Maitri Enterprises Limited |
| Rakesh S Lakhani DIN 09239137 | Director | 14 Jul 2021 | 5 yrs 3 mo | Maitri Enterprises Limited |
| Bharat Ramjibhai Sisodia DIN 11327540 | Additional Director | 14 Nov 2025 | 11 mo | Maitri Enterprises Limited |
People of Maitri Enterprises
1 people are tracked at Maitri Enterprises (1 in leadership).
| Name | Role | Group |
|---|---|---|
| Managing Director | Leadership |
Complete people profiles for Maitri Enterprises
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Maitri Enterprises
Maitri Enterprises is a publicly listed company on the BSE with ticker symbol MAITRI in India, operating in the Non-energy minerals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Nov 2011
- Listed onBSE: 513430
- Listed entityMaitri Enterprises Ltd.
- Exchange sectorNon-energy minerals
- ISININE501L01024
- Share price₹41.00 · 2026-10-13
- Volume (last session)1
Financials of Maitri Enterprises
Exchange-reported figures of Maitri Enterprises Limited, the listed company behind Maitri Enterprises (BSE: MAITRI).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 33.30 | 28.70 | 19.01 | 13.33 | 20.09 |
| Revenue growth | +16.0% | +51.0% | +42.6% | -33.7% | - |
| EBITDA | 1.29 | 1.13 | 0.24 | 0.51 | 0.69 |
| EBITDA margin | +3.9% | +3.9% | +1.3% | +3.8% | +3.4% |
| Profit before tax | 0.92 | 0.33 | (0.42) | 0.18 | 0.34 |
| Net profit | 0.60 | 0.96 | (0.46) | 0.02 | 0.23 |
| Net profit margin | +1.8% | +3.3% | -2.4% | +0.2% | +1.1% |
| EPS (βΉ) | 1.37 | 0.38 | (1.02) | 0.00 | 0.51 |
| Balance sheet | |||||
| Total assets | 10.18 | 11.61 | 15.09 | 11.31 | 10.69 |
| Net worth | 5.26 | 4.70 | 4.52 | 4.97 | 4.97 |
| Total debt | 4.83 | 6.89 | 10.54 | 6.34 | 5.72 |
| Cash & bank | 0.51 | 0.43 | 0.55 | 0.45 | 0.42 |
| Net working capital | 5.84 | 7.43 | 9.73 | 9.48 | 9.03 |
| Cash flow | |||||
| Cash from operations | 3.09 | 3.04 | 0.06 | 0.02 | (0.39) |
| Cash from investing | (0.24) | 1.23 | (3.45) | (0.24) | (3.27) |
| Cash from financing | (2.76) | (4.40) | 3.49 | 0.24 | 3.69 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.20 | 13.91 | 4.66 | 7.76 | 6.97 | 5.88 | 7.71 | 7.34 |
| Revenue growth (YoY) | -25.4% | +136.6% | -39.6% | +5.7% | -9.7% | - | - | - |
| Other income | 0.00 | 0.04 | 0.01 | 0.30 | 0.07 | (0.06) | 0.02 | 0.08 |
| EBITDA | (0.28) | 0.79 | 0.90 | 0.31 | (0.70) | (0.31) | 0.22 | 0.94 |
| EBITDA margin | -5.4% | +5.7% | +19.3% | +4.0% | -10.0% | -5.3% | +2.9% | +12.8% |
| Depreciation | 0.03 | 0.01 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Interest | 0.08 | 0.15 | 0.19 | 0.20 | 0.18 | 0.13 | 0.19 | 0.42 |
| Profit before tax | (0.39) | 0.67 | 0.69 | 0.39 | (0.83) | (0.52) | 0.03 | 0.58 |
| Tax | 0.08 | 0.21 | 0.27 | (0.02) | (0.14) | (0.49) | 0.43 | 0.16 |
| Net profit | (0.47) | 0.46 | 0.42 | 0.41 | (0.69) | (0.03) | (0.40) | 0.42 |
| EPS (βΉ) | (1.05) | 1.07 | 0.95 | 0.93 | (1.58) | (0.04) | (0.89) | 0.99 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 32.19 | 28.66 | 18.35 | 9.90 | 12.58 | 4.55 | 6.66 |
| Revenue growth | +12.3% | +56.2% | +85.4% | -21.3% | +176.5% | -31.7% | - |
| EBITDA | 1.36 | 1.21 | 0.46 | 0.58 | 0.41 | 0.09 | (0.01) |
| EBITDA margin | +4.2% | +4.2% | +2.5% | +5.9% | +3.3% | +2.0% | -0.2% |
| Profit before tax | 1.14 | 0.45 | 0.12 | 0.46 | 0.30 | 0.10 | 0.21 |
| Net profit | 0.82 | 1.14 | 0.08 | 0.32 | 0.22 | 0.06 | 0.16 |
| Net profit margin | +2.6% | +4.0% | +0.4% | +3.2% | +1.8% | +1.3% | +2.4% |
| EPS (βΉ) | 1.85 | 0.68 | 0.18 | 0.77 | 0.50 | 0.38 | 0.86 |
| Balance sheet | |||||||
| Total assets | 10.86 | 12.01 | 15.40 | 7.71 | 6.73 | 2.45 | 2.08 |
| Net worth | 6.47 | 5.69 | 5.38 | 5.30 | 4.96 | 2.04 | 1.97 |
| Total debt | 4.30 | 6.30 | 9.99 | 2.41 | 1.77 | 0.40 | 0.11 |
| Cash & bank | 0.30 | 0.33 | 0.34 | 0.26 | 0.16 | 0.18 | 0.14 |
| Net working capital | 2.94 | 3.48 | 5.15 | 2.89 | 2.10 | 1.17 | 0.96 |
| Cash flow | |||||||
| Cash from operations | 1.56 | 2.60 | (1.70) | (0.20) | (0.62) | (0.17) | 0.64 |
| Cash from investing | 1.07 | 1.78 | (5.24) | (0.26) | (3.39) | (0.06) | (0.62) |
| Cash from financing | (2.65) | (4.39) | 7.03 | 0.55 | 3.99 | 0.27 | (0.01) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.20 | 13.61 | 4.66 | 7.76 | 6.17 | 5.88 | 7.71 | 7.33 |
| Revenue growth (YoY) | -15.7% | +131.5% | -39.6% | +5.9% | -19.8% | - | - | - |
| Other income | 0.02 | 0.24 | 0.04 | 0.11 | 0.11 | (0.06) | 0.02 | 0.08 |
| Total expenses | 4.86 | 12.78 | 3.76 | 7.38 | 6.91 | 6.17 | 7.48 | 6.34 |
| EBITDA | 0.34 | 0.83 | 0.90 | 0.38 | (0.74) | (0.29) | 0.23 | 0.99 |
| EBITDA margin | +6.5% | +6.1% | +19.3% | +4.9% | -12.0% | -4.9% | +3.0% | +13.5% |
| Depreciation | 0.02 | 0.01 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Interest | 0.07 | 0.14 | 0.17 | 0.19 | 0.16 | 0.12 | 0.17 | 0.41 |
| Profit before tax | 0.27 | 0.92 | 0.74 | 0.28 | (0.81) | (0.49) | 0.06 | 0.64 |
| Tax | 0.08 | 0.21 | (0.18) | (0.02) | (0.14) | (0.49) | 0.43 | 0.16 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.20 | 13.91 | 4.66 | 7.76 | 6.97 | 5.88 | 7.71 | 7.34 |
| Revenue growth (YoY) | -25.4% | +136.6% | -39.6% | +5.7% | -9.7% | - | - | - |
| Other income | 0.00 | 0.04 | 0.01 | 0.30 | 0.07 | (0.06) | 0.02 | 0.08 |
| EBITDA | (0.28) | 0.79 | 0.90 | 0.31 | (0.70) | (0.31) | 0.22 | 0.94 |
| EBITDA margin | -5.4% | +5.7% | +19.3% | +4.0% | -10.0% | -5.3% | +2.9% | +12.8% |
| Depreciation | 0.03 | 0.01 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Interest | 0.08 | 0.15 | 0.19 | 0.20 | 0.18 | 0.13 | 0.19 | 0.42 |
| Profit before tax | (0.39) | 0.67 | 0.69 | 0.39 | (0.83) | (0.52) | 0.03 | 0.58 |
| Tax | 0.08 | 0.21 | 0.27 | (0.02) | (0.14) | (0.49) | 0.43 | 0.16 |
| Net profit | (0.47) | 0.46 | 0.42 | 0.41 | (0.69) | (0.03) | (0.40) | 0.42 |
| EPS (βΉ) | (1.05) | 1.07 | 0.95 | 0.93 | (1.58) | (0.04) | (0.89) | 0.99 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Revenue | 33.30 | 28.70 | 19.01 | 13.33 | 20.09 |
| Revenue growth | +16.0% | +51.0% | +42.6% | -33.7% | - |
| Other income | 0.42 | 0.04 | 0.13 | 0.11 | 0.06 |
| Total expenses | 32.01 | 27.57 | 18.77 | 12.82 | 19.40 |
| Employee cost | 0.00 | 0.72 | 0.95 | 0.75 | 0.80 |
| EBITDA | 1.29 | 1.13 | 0.24 | 0.51 | 0.69 |
| EBITDA margin | +3.9% | +3.9% | +1.3% | +3.8% | +3.4% |
| Depreciation | 0.08 | 0.07 | 0.06 | 0.07 | 0.09 |
| Interest | 0.71 | 0.77 | 0.73 | 0.37 | 0.32 |
| Profit before tax | 0.92 | 0.33 | (0.42) | 0.18 | 0.34 |
| Tax | 0.32 | 0.16 | 0.04 | 0.16 | 0.11 |
| Net profit | 0.60 | 0.96 | (0.46) | 0.02 | 0.23 |
| Net profit margin | +1.8% | +3.3% | -2.4% | +0.2% | +1.1% |
| EPS (βΉ) | 1.37 | 0.38 | (1.02) | 0.00 | 0.51 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Equity & liabilities | |||||
| Share capital | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 |
| Reserves & surplus | 0.86 | 0.30 | 0.12 | 0.57 | 0.57 |
| Shareholders' funds (net worth) | 5.26 | 4.70 | 4.52 | 4.97 | 4.97 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 2.22 | 2.95 | 0.03 | 1.74 | 0.05 |
| Unsecured loans | 2.61 | 3.94 | 10.51 | 4.60 | 5.67 |
| Total debt | 4.83 | 6.89 | 10.54 | 6.34 | 5.72 |
| Total liabilities | 10.18 | 11.61 | 15.09 | 11.31 | 10.69 |
| Assets | |||||
| Gross block | 1.13 | 0.90 | 0.82 | 0.76 | 0.73 |
| Net block | 0.39 | 0.24 | 0.23 | 0.23 | 0.28 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 3.74 | 3.74 | 3.92 | 0.27 | 0.27 |
| Inventories | 4.14 | 5.73 | 6.50 | 7.92 | 6.13 |
| Sundry debtors | 5.19 | 5.41 | 8.75 | 7.47 | 8.94 |
| Cash & bank balances | 0.51 | 0.43 | 0.55 | 0.45 | 0.42 |
| Loans & advances | 0.45 | 0.61 | 0.52 | 0.73 | 0.39 |
| Total current assets | 10.29 | 12.18 | 16.32 | 16.57 | 15.88 |
| Total current liabilities | 4.45 | 4.75 | 6.59 | 7.09 | 6.85 |
| Net working capital | 5.84 | 7.43 | 9.73 | 9.48 | 9.03 |
| Total assets | 10.18 | 11.61 | 15.09 | 11.31 | 10.69 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Opening cash | 0.43 | 0.55 | 0.45 | 0.42 | 0.39 |
| Net cash from operating activities | 3.09 | 3.04 | 0.06 | 0.02 | (0.39) |
| Net cash from investing activities | (0.24) | 1.23 | (3.45) | (0.24) | (3.27) |
| Net cash from financing activities | (2.76) | (4.40) | 3.49 | 0.24 | 3.69 |
| Net change in cash | 0.09 | (0.12) | 0.10 | 0.02 | 0.03 |
| Closing cash | 0.51 | 0.43 | 0.55 | 0.45 | 0.42 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Growth | |||||
| Sales growth | +16.0% | +51.0% | +42.6% | -33.7% | - |
| EBITDA growth | +14.2% | +370.8% | -52.9% | -26.1% | - |
| PBT growth | +178.8% | +9998.0% | - | -47.1% | +9997.0% |
| Net income growth | -37.5% | +308.7% | -2400.0% | -91.3% | - |
| Revenue CAGR (3Y) | +35.7% | +12.6% | - | - | - |
| EBITDA CAGR (3Y) | +36.3% | +17.9% | - | - | - |
| Profitability & leverage | |||||
| Net income margin | +1.8% | +0.6% | -2.4% | +0.2% | +1.1% |
| Return on capital employed | - | +15.8% | 0.0% | +4.9% | +6.2% |
| Return on net worth | - | +20.8% | 0.0% | 0.0% | +4.6% |
| Debt / equity | - | 1.89 | 1.78 | 1.21 | 1.15 |
| Long-term debt / equity | - | 1.49 | 1.14 | 0.42 | 0.64 |
| Interest cover | 58.68 | 72.64 | 405.56 | 84.09 | 53.33 |
| Efficiency & per share | |||||
| Fixed asset turnover | - | 33.37 | 24.06 | 17.89 | 27.52 |
| Inventory turnover | - | 4.69 | 2.64 | 1.90 | 3.28 |
| Debtors turnover | - | 4.05 | 2.34 | 1.62 | 2.25 |
| EPS (βΉ) | 1.37 | 0.38 | (1.02) | 0.00 | 0.51 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 0.00 | 10.67 | 10.27 | 11.29 | 11.29 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.20 | 13.61 | 4.66 | 7.76 | 6.17 | 5.88 | 7.71 | 7.33 |
| Revenue growth (YoY) | -15.7% | +131.5% | -39.6% | +5.9% | -19.8% | - | - | - |
| Other income | 0.02 | 0.24 | 0.04 | 0.11 | 0.11 | (0.06) | 0.02 | 0.08 |
| Total expenses | 4.86 | 12.78 | 3.76 | 7.38 | 6.91 | 6.17 | 7.48 | 6.34 |
| EBITDA | 0.34 | 0.83 | 0.90 | 0.38 | (0.74) | (0.29) | 0.23 | 0.99 |
| EBITDA margin | +6.5% | +6.1% | +19.3% | +4.9% | -12.0% | -4.9% | +3.0% | +13.5% |
| Depreciation | 0.02 | 0.01 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Interest | 0.07 | 0.14 | 0.17 | 0.19 | 0.16 | 0.12 | 0.17 | 0.41 |
| Profit before tax | 0.27 | 0.92 | 0.74 | 0.28 | (0.81) | (0.49) | 0.06 | 0.64 |
| Tax | 0.08 | 0.21 | (0.18) | (0.02) | (0.14) | (0.49) | 0.43 | 0.16 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 32.19 | 28.66 | 18.35 | 9.90 | 12.58 | 4.55 | 6.66 |
| Revenue growth | +12.3% | +56.2% | +85.4% | -21.3% | +176.5% | -31.7% | - |
| Other income | 0.51 | 0.04 | 0.26 | 0.03 | 0.03 | 0.08 | 0.27 |
| Total expenses | 30.83 | 27.45 | 17.89 | 9.32 | 12.17 | 4.46 | 6.67 |
| Employee cost | 0.00 | 0.72 | 0.93 | 0.57 | 0.58 | 0.36 | 0.27 |
| EBITDA | 1.36 | 1.21 | 0.46 | 0.58 | 0.41 | 0.09 | (0.01) |
| EBITDA margin | +4.2% | +4.2% | +2.5% | +5.9% | +3.3% | +2.0% | -0.2% |
| Depreciation | 0.07 | 0.07 | 0.05 | 0.06 | 0.07 | 0.05 | 0.04 |
| Interest | 0.66 | 0.73 | 0.55 | 0.09 | 0.07 | 0.02 | 0.01 |
| Profit before tax | 1.14 | 0.45 | 0.12 | 0.46 | 0.30 | 0.10 | 0.21 |
| Tax | 0.32 | 0.16 | 0.04 | 0.14 | 0.08 | 0.04 | 0.05 |
| Net profit | 0.82 | 1.14 | 0.08 | 0.32 | 0.22 | 0.06 | 0.16 |
| Net profit margin | +2.6% | +4.0% | +0.4% | +3.2% | +1.8% | +1.3% | +2.4% |
| EPS (βΉ) | 1.85 | 0.68 | 0.18 | 0.77 | 0.50 | 0.38 | 0.86 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 | 1.90 | 1.90 |
| Reserves & surplus | 2.07 | 1.29 | 0.98 | 0.90 | 0.56 | 0.14 | 0.07 |
| Shareholders' funds (net worth) | 6.47 | 5.69 | 5.38 | 5.30 | 4.96 | 2.04 | 1.97 |
| Secured loans | 2.22 | 2.95 | 0.03 | 0.03 | 0.05 | 0.08 | 0.00 |
| Unsecured loans | 2.08 | 3.35 | 9.96 | 2.38 | 1.72 | 0.32 | 0.11 |
| Total debt | 4.30 | 6.30 | 9.99 | 2.41 | 1.77 | 0.40 | 0.11 |
| Total liabilities | 10.86 | 12.01 | 15.40 | 7.71 | 6.73 | 2.45 | 2.08 |
| Assets | |||||||
| Gross block | 0.86 | 0.63 | 0.55 | 0.49 | 0.46 | 0.43 | 0.27 |
| Net block | 0.33 | 0.17 | 0.16 | 0.15 | 0.18 | 0.22 | 0.10 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 6.83 | 6.83 | 7.02 | 3.37 | 3.37 | 0.00 | 0.00 |
| Inventories | 4.14 | 4.67 | 5.36 | 5.93 | 4.16 | 3.14 | 2.23 |
| Sundry debtors | 2.49 | 2.30 | 5.26 | 1.86 | 2.33 | 1.57 | 1.10 |
| Cash & bank balances | 0.30 | 0.33 | 0.34 | 0.26 | 0.16 | 0.18 | 0.14 |
| Loans & advances | 0.41 | 0.62 | 0.45 | 0.60 | 0.36 | 0.23 | 0.07 |
| Total current assets | 7.34 | 7.92 | 11.41 | 8.65 | 7.01 | 5.12 | 3.54 |
| Total current liabilities | 4.40 | 4.44 | 6.26 | 5.76 | 4.91 | 3.95 | 2.58 |
| Net working capital | 2.94 | 3.48 | 5.15 | 2.89 | 2.10 | 1.17 | 0.96 |
| Total assets | 10.86 | 12.01 | 15.40 | 7.71 | 6.73 | 2.45 | 2.08 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.33 | 0.34 | 0.26 | 0.16 | 0.18 | 0.14 | 0.12 |
| Net cash from operating activities | 1.56 | 2.60 | (1.70) | (0.20) | (0.62) | (0.17) | 0.64 |
| Net cash from investing activities | 1.07 | 1.78 | (5.24) | (0.26) | (3.39) | (0.06) | (0.62) |
| Net cash from financing activities | (2.65) | (4.39) | 7.03 | 0.55 | 3.99 | 0.27 | (0.01) |
| Net change in cash | (0.03) | (0.02) | 0.09 | 0.09 | (0.01) | 0.04 | 0.01 |
| Closing cash | 0.30 | 0.33 | 0.34 | 0.26 | 0.16 | 0.18 | 0.14 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +12.3% | +56.2% | +85.4% | -21.3% | +176.5% | -31.7% | - |
| EBITDA growth | +12.4% | +163.0% | -20.7% | +41.5% | +355.6% | +1000.0% | - |
| PBT growth | +153.3% | +275.0% | -73.9% | +53.3% | +200.0% | -52.4% | +2000.0% |
| Net income growth | -28.1% | +1325.0% | -75.0% | +45.5% | +266.7% | -62.5% | - |
| Revenue CAGR (3Y) | +48.2% | +31.6% | +59.2% | +14.1% | +26.9% | +87.5% | +118.3% |
| EBITDA CAGR (3Y) | +32.9% | +43.4% | +72.3% | - | - | - | -41.5% |
| Profitability & leverage | |||||||
| Net income margin | +2.6% | +1.0% | +0.4% | +3.2% | +1.8% | +1.3% | +2.4% |
| Return on capital employed | - | +16.1% | +5.8% | +7.8% | +8.1% | +5.8% | +11.1% |
| Return on net worth | - | +20.8% | +1.5% | +6.6% | +6.3% | +3.5% | +8.3% |
| Debt / equity | - | 1.47 | 1.16 | 0.41 | 0.31 | 0.13 | 0.03 |
| Long-term debt / equity | - | 1.20 | 0.95 | 0.03 | 0.06 | 0.12 | 0.03 |
| Interest cover | 51.16 | 64.04 | 134.15 | 17.31 | 20.59 | 50.00 | -20.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 48.58 | 35.29 | 20.84 | 28.27 | 13.00 | 25.13 |
| Inventory turnover | - | 5.71 | 3.25 | 1.96 | 3.45 | 1.69 | 3.18 |
| Debtors turnover | - | 7.58 | 5.15 | 4.73 | 6.45 | 3.41 | 5.37 |
| EPS (βΉ) | 1.85 | 0.68 | 0.18 | 0.77 | 0.50 | 0.38 | 0.86 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 0.00 | 12.93 | 12.23 | 12.05 | 11.28 | 10.76 | 10.38 |
Similar companies to Maitri Enterprises
Maitri Enterprises has 3 listed similar companies in our database, 3 of them funded. They include Entero Healthcare, Keimed and Sandor Medicaids.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| enterohealthcare.com | 2018 | Mumbai, India | $59.67M | 817 | India's leading healthcare products distribution platform | |
| keimed.com | 2000 | Hyderabad, India | $16.62M | 588 | Temperature-sensitive medicines are distributed via cold chain logistics by Keimed. | |
| sandor.co.in | 1995 | Hyderabad, India | $8.98M | 161 | Provider of medical equipment, devices, and drugs distribution services |
Detailed similar companies of Maitri Enterprises
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Maitri Enterprises
Complete news archive for Maitri Enterprises
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Maitri Enterprises
Maitri Enterprises was founded in 1991.
Maitri Enterprises is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.
The primary company behind Maitri Enterprises, Maitri Enterprises Limited, reported revenue of βΉ33.72 Cr for FY 2026, up 16% year on year.
Maitri Enterprises was established in 1991 and is headquartered in Ahmedabad, India. Operations focus on the distribution of pharmaceutical products and medical devices within the healthcare sector. The company is managed by Jaikishan R Ambwani as Managing Director. Activities encompass supply chain logistics and product sourcing for regional markets, supporting medical and pharmaceutical needs across the country.
Maitri Enterprises's top competitors include Entero Healthcare, Keimed and Sandor Medicaids.
Maitri Enterprises offers Corporate Services.
Yes, Maitri Enterprises is publicly traded on BSE under the ticker symbol MAITRI.
Maitri Enterprises is associated with 2 legal entities: Maitri Enterprises Limited, Dr Zag Ambwani (India) Llp.
The legal entities of Maitri Enterprises currently have 9 directors, including Nilesh Carpenter, Sarla Jaikishan Ambwani, Jaikishan Rameshlal Ambwani and others.
